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Abstract
The aim of this study was to assess changes in antibiotic resistance, epidemiology and outcome among patients with Enterococcus faecalis
infective endocarditis (EFIE) and to compare the efficacy and safety of the combination of ampicillin and gentamicin (A+G) with that of
ampicillin plus ceftriaxone (A+C). The study was a retrospective analysis of a prospective cohort of EFIE patients treated in our centre from
1997 to 2011. Thirty patients were initially treated with A+G (ampicillin 2 g/4 h and gentamicin 3 mg/kg/day) and 39 with A+C (ampicillin
2 g/4 h and ceftriaxone 2 g/12 h) for 4–6 weeks. Increased rates of high-level aminoglycoside resistance (HLAR; gentamicin MIC ≥512 mg/
L, streptomycin MIC ≥1024 mg/L or both) were observed in recent years (24% in 1997–2006 and 49% in 2007–2011; p 0.03). The use of
A+C increased over time: 1997–2001, 4/18 (22%); 2002–2006, 5/16 (31%); 2007–2011, 30/35 (86%) (p <0.001). Renal failure developed in
65% of the A+G group and in 34% of the A+C group (p 0.014). Thirteen patients (43%) in the A+G group had to discontinue treatment,
whereas only one patient (3%) treated with A+C had to discontinue treatment (p <0.001). Only development of heart failure and previous
chronic renal failure were independently associated with 1-year mortality, while the individual antibiotic regimen (A+C vs. A+G) did not
affect outcome (OR, 0.7; 95% CI, 0.2–2.2; p 0.549). Our study shows that the prevalence of HLAR EFIE has increased significantly in recent
years and that alternative treatment with A+C is safer than A+G, with similar clinical outcomes, although the sample size is too small to
draw firm conclusions. Randomized controlled studies are needed to confirm these results.
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Introduction
Enterococci are the third most common causal agent of
infective endocarditis (IE) worldwide [1] and are becoming
increasingly prevalent among the elderly [2], in patients with
comorbidities [3,4], and when endocarditis is acquired in the
healthcare setting [5,6]. The growing prevalence of entero-
cocci is due to a progressive increase in the number of
urogenital and abdominal procedures and an increase in the
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number of cases of enterococcal catheter-related bacteraemia,
thus highlighting the role of nosocomial acquisition, which is
associated with higher mortality [6]. Enterococci produce
predominantly left-sided IE, and a third of all cases of
prosthetic valve (PV) IE [6–8]; approximately 90% of cases
are due to Enterococcus faecalis and less than 5% are caused by
Enterococcus faecium [3].
The mortality rate of enterococcal IE has not changed
during the last three decades [9], but resistance to classic
treatment options has emerged [10]. High-level aminoglyco-
side resistance (HLAR) in the case of E. faecalis endocarditis
(EFIE) is particularly worrisome, because no randomized trials
have provided high-quality data on alternatives to the classic
combination of ampicillin plus an aminoglycoside (mainly
gentamicin, A+G) to treat the disease. Ampicillin combined
with an aminoglycoside has been the first choice for EFIE from
the 1950s, when synergy was proven [11], and has been
recommended in the AHA guidelines ever since [12]. How-
ever, this combination has disadvantages other than rising rates
of HLAR, namely nephrotoxicity. A decade ago, Olaison and
Schadewitz [13] proposed shortening the course of amino-
glycoside to 2–3 weeks based on favourable results in a large
series of 91 cases of EFIE. However, the most important
advance in the last two decades has been the proven efficacy
and safety profile of ampicillin plus ceftriaxone (A+C) [14].
Although A+C has been included in American and European
guidelines as an alternative to treat HLAR EFIE [12,15],
evidence from prospective studies comparing these two
combinations is limited. Our objective was to assess changes
in resistance to antibiotics, epidemiology and outcome of
patients with EFIE during the last 15 years. We also compared
the efficacy and safety of the combination of A+G and A+C for
the treatment of EFIE.
Methods
Design
We performed a retrospective study of prospectively
collected cases comprising a cohort who attended an urban
tertiary care hospital with 850 beds. All consecutive entero-
coccal IE episodes diagnosed between January 1997 and
December 2011 were collected in a specific database using a
standardized case report form. The study population com-
prised patients with a definitive diagnosis of IE [16] caused by
E. faecalis who were receiving treatment with A+G or A+C
and whose antimicrobial sensitivity patterns were available.
Outcomes were attributed to the initial treatment (inten-
tion-to-treat analysis). All survivors were followed for at
least 1 year.
Antimicrobial treatment
Antimicrobial treatment for non-HLAR EFIE was administered
according to American and European recommendations
[12,15]. Ampicillin was administered at a dose of 2 g/4 h and
gentamicin at 3 mg/kg/24 h. Gentamicin levels were moni-
tored following AHA guidelines [12]. A+C (ampicillin 2 g/4 h
and ceftriaxone 2 g/12 h) was administered to patients with
and without HLAR based on the favourable results obtained in
an open-label non-randomized trial in Spain from 1995 to 2003
[14]. Ten of the patients who comprise the present cohort
were included in that study. Length of standard treatment with
both combinations was 28 days for non-complicated native
valve (NV) IE and 42 days for PVIE or complicated IE.
Definitions
The variables analysed are depicted in Tables 1 and 2 and
defined elsewhere [5].
Adverse events were considered related to treatment when
renal failure or cochleo-vestibular toxicity developed with
aminoglycosides and leukopenia or skin rash developed with
betalactams. Renal failure was measured using creatinine, and
the glomerular filtration rate (at baseline, at the end of
admission, and in the case of treatment switch) was assessed
according to the Modification of Diet in Renal Disease formula
[18]. Acute renal impairment or failure was defined as a
sudden increase (≤48 h) in serum creatinine of ≥0.3 mg/dL or
an increase of ≥50% over baseline creatinine during a 7-day
period or diuresis ≤0.5 mL/kg/h in 6 h [19], regardless of the
presence or absence of previous chronic impairment (with the
exception of patients undergoing haemodialysis, who were not
included in this analysis). The definitions of ototoxicity related
to aminoglycosides and side-effects of betalactams were those
of previous studies [20,21].
Relapse was defined as a new episode of IE caused by the
same microorganism during the 6 months after treatment.
In-hospital mortality included death during the admission for
the EFIE episode; 1-year mortality included death during the
365 days following the diagnosis of EFIE.
High-level aminoglycoside resistance for gentamicin, strep-
tomycin or both was included in the epidemiological analysis
during the study period. We used the variable high-level
gentamicin resistance (HLGR) to analyse clinical outcomes,
because no patients were treated with streptomycin and,
therefore, high-level streptomycin resistance was assumed to
have no impact on the type of antimicrobial regimen admin-
istered or on outcome.
The epidemiological analysis of the evolution of HLAR was
performed and the type of antimicrobial therapy analysed
according to three periods of time: 1997–2001, 2002–2006
and 2007–2011.
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Microbiological sample processing and definitions of HLAR
In all 69 cases with a diagnosis of EFIE, E. faecalis isolates
were recovered and frozen in skimmed milk at 80°C.
Strains were identified using the API Rapid ID32 STREP
device (bioMerieux, Marcy l’Etoile, France). HLAR was
assessed using the Etest following the manufacturer’s
recommendations (bioMerieux). HLAR was defined as
follows: gentamicin MIC ≥512 mg/L, streptomycin MIC
TABLE 1. Clinical characteristics
and outcome of 69 episodes of
Enterococcus faecalis infective endo-
carditis according to the presence or
absence of HLGR
HLGRa
(N = 13)
Non-HLGR
(N = 56) p
Median age (IQR) 72.0 (65–80) 71.0 (64.5–77) 0.763
Male gender (%) 7 (54) 37 (66) 0.524
Year of diagnosis (%)
1997–2001 1 (8) 17 (30) 0.018
2002–2006 1 (8) 15 (27)
2007–2011 11 (84) 24 (43)
Predisposing conditions and underlying diseases (%)
Diabetes mellitus 5 (39) 18 (32) 0.748
Chronic renal failure 3 (23) 14 (25) 1.000
Haemodialysisb 1 (8) 4 (7) 1.000
History of cancer 4 (31) 12 (21) 0.481
HIV infection 0 1 (2) 1.000
Chronic liver disease 2 (15) 6 (11) 0.639
Chronic lung disease 3 (23) 12 (21) 1.000
Transplantation 0 1 (2) 1.000
History of infective endocarditis 2 (15) 7 (13) 0.674
Median Charlson comorbidity index (IQR) 2.0 (1–3) 3.0 (1–4) 0.221
Presumed mode of acquisition (%)
Nosocomial 4 (31) 32 (57) 0.008
Non-nosocomial healthcare-associated 7 (54) 8 (14)
Community-acquired 2 (15) 16 (29)
Source of infection (%)
Unknown 3 (23) 29 (52) 0.319
Catheter 1 (8) 3 (5)
Urinary 5 (39) 13 (23)
Abdominal/digestive tract 4 (31) 11 (20)
Median days of symptoms until diagnosis (IQR) 7.0 (1.5–20) 15.0 (2–45) 0.197
Type of endocarditis (%)
Native 8 (61) 37 (66) 0.735
Prosthetic valve 5 (39) 17 (30)
Pacemaker leadc 2 (16) 2 (4)
Valve involvement (%)
Aortic valve 5 (39) 25 (45) 0.194
Mitral valve 2 (15) 20 (36)
Pacemaker/intracardiac device lead 2 (15) 1 (2)
Mitral + aortic 2 (15) 7 (13)
Tricuspid + aortic 1 (8) 0
Tricuspid + aortic + mitral 0 1 (2)
Pulmonary 1 (8) 2 (3)
Echocardiographic findings
Presence of vegetation (%) 8 (62) 45 (80) 0.294
Vegetation size in mm, median (IQR) 14 (8–18) 10 (5–13) 0.593
Perivalvular abscess (%) 1 (8) 7 (13) 1.000
Complications (%)
Heart failure 8 (63) 25 (45) 0.272
Systemic emboli 2 (15) 19 (34) 0.317
Relapses 1 (8) 4 (5) 1.000
Toxicity
Baseline GFR in mL/min, median (IQR) 69.0 (39.5–99) 60.0 (44–86) 0.133
Baseline creatinine in mg/dL, median (IQR) 0.8 (0.7–1.4) 1.1 (0.9–1.4) 0.431
Occurrence of renal failure during treatmentd (%) 3 (25) 27 (52) 0.092
GFR at the end of therapy, median (IQR) 46.0 (26–79) 49.0 (34–67) 0.553
Total GFR change during therapy; median (IQR) 20.0, 12 to 28 1.5, 19 to 15 0.088
Ototoxicity (%) 0 2 (4) 1.000
Vestibular toxicity (%) 0 1 (2) 1.000
Skin rash (%) 0 2 (4) 1.000
Myelotoxicity (%) 1 (8) 0 0.188
Median duration of treatment in days (IQR) 42.0 (28–42) 42.0 (28–42) 1.000
Median duration of aminoglycosides in days (IQR) NA 28.0 (15–32) –
Type of aminoglycoside regimen (%)
QD NA 1 (2) –
BID 6 (11)
TID 23 (41)
Surgical treatment 4 (31) 26 (46) 0.305
Mortality (%)
In-hospital mortality 2 (15) 15 (27) 0.390
1-year mortality 3 (23) 16 (29) 1.000
NA, not applicable.
aHLGR includes patients with high-level resistance to gentamicin (6) and patients with high-level resistance to both
gentamicin and streptomycin (7). Non-HLGR includes 12 patients with high-level resistance to streptomycin.
bThe five patients on haemodialysis are not included in the analysis of renal function and development of renal failure/
toxicity.
cThe two patients with intracardiac devices also had prosthetic valve IE.
dIn all the patients who developed renal failure during treatment, baseline creatinine increased by ≥50% in ≤48 h.
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≥1024 mg/L, or both gentamicin MIC ≥512 mg/L and strep-
tomycin MIC ≥1024 mg/L.
Statistical analysis
Comparisons between groups were performed according to
three main variables: type of endocarditis (NV vs. PV/
pacemaker), type of initial antimicrobial treatment (A+G vs.
A+C), and the presence or absence of HLGR. Categorical
variables are summarized as percentages. Continuous variables
are summarized as median and interquartile range (IQR).
Categorical variables were compared using the chi-square test
(or Fisher’s exact test when necessary). The Mantel–Haenszel
test for trend was applied to find significant differences in
HLAR throughout the study. We used Kaplan–Meier survival
analysis to analyse 1-year mortality and treatment discontin-
uation according to the regimen taken. Curves were compared
using the log-rank test. Predictors with a p value <0.30 were
included in the logistic regression analysis, which was per-
formed using a likelihood ratio-based backward exclusion
method. A two-sided p <0.05 was considered to be statisti-
cally significant. The statistical analysis was performed using
SPSS version 16.0 (SPSS Inc, Chicago, IL, USA).
Results
Epidemiological and clinical characteristics of EFIE
During the study period, we diagnosed 80 episodes of
enterococcal IE, which accounted for 13% of the 620 cases
of IE diagnosed at our institution. Eleven of these cases were
excluded from the analysis (two cases of E. faecium IE, five
treated with combinations other than A+G or A+C, two
because of lack of data (early death), and two cases of
polymicrobial IE). Twenty patients (29%) were referred from
other centres. Median time of follow-up was 392 days (IQR,
118.5–792.0). The clinical characteristics and outcome of these
69 cases are summarized according to the presence or
absence of HLGR in Table 1. Forty-six cases (67%) were NVIE,
21 (30%) were PVIE and two (3%) had pacemaker-related
infections. There were five relapses (7%).
Evolution of HLAR over time and influence on prognosis
Twenty-five isolates presented HLAR (36%). A trend towards
higher total HLAR rates was observed in more recent years
(p 0.095) (Fig. 1a). High-level resistance to gentamicin, strep-
tomycin and both aminoglycosides increased between 1997–
2006 and 2007–2011: 6% vs. 31% (p 0.007), 21% vs. 34%
(p 0.203) and 24% vs. 49% (p 0.030), respectively. Patient
characteristics, antibiotic treatment and outcome according to
the presence or absence of HLGR in the strains causing EFIE
TABLE 2. Clinical characteristics and outcome of 69 epi-
sodes of Enterococcus faecalis infective endocarditis according
to the type of antimicrobial treatment administered
A+G (N = 30) A+C (N = 39) p
Median age in years (IQR) 75.0 (68–77) 70.0 (63–78) 0.289
Male gender (%) 22 (73) 22 (56) 0.147
HLARa (%) 7 (23) 18 (46) 0.051
Year of diagnosis (%)
1996–2001 14 (47) 4 (10) <0.001
2002–2006 11 (37) 5 (13)
2007–2011 5 (17) 30 (77)
Predisposing conditions
and underlying diseases (%)
Diabetes mellitus 11 (37) 12 (31) 0.606
Haemodialysis 4 (13) 1 (3) 0.159
History of cancer 7 (23) 9 (23) 0.980
HIV infection 0 1 (3) 1.000
Chronic liver disease 1 (3) 3 (18) 0.125
Chronic lung disease 7 (23) 8 (21) 0.778
Transplantation 0 1 (3) 1.000
History of infective
endocarditis
2 (7) 7 (18) 0.281
Median Charlson score
(IQR)
2.0 (1–3) 3.0 (1–4) 0.766
Presumed mode of
acquisition (%)
Nosocomial 19 (63) 17 (44) 0.207
Non-nosocomial
healthcare-associated
4 (13) 11 (28)
Community-acquired 7 (23) 11 (28)
Type of endocarditis (%)
Native valve 20 (67) 25 (64) 1.000
Prosthetic valve 9 (30) 13 (33)
Pacemaker lead 1 (3) 1 (3)
Valve involvement (%)
Aortic valve 19 (63) 25 (64) 0.394
Mitral valve 9 (30) 13 (33)
Right-sided/intracardiac
device
2 (7) 1 (3)
Echocardiographic findings
Presence of vegetation 25 (84%) 28 (72%) 0.260
Vegetation size in mm,
median (IQR)
10 (5–14) 9.5 (6–13) 0.659
Perivalvular abscess 5 (17%) 3 (8%) 0.281
Complications (%)
Heart failure 13 (43) 20 (51) 0.512
Renal failure 17 (65) 13 (34) 0.014
Systemic emboli 8 (27) 13 (33) 0.551
Persistent bacteraemia 2 (4) 7 (10) 0.690
Toxicityb
Renal failure at baseline 8 (27%) 9 (23%) 0.732
Baseline GFR in mL/min,
median (IQR)
58.5 (44–81) 61.0 (44–92) 0.112
Baseline creatinine
in mg/dL,
median (IQR)
1.2 (0.9–1.7) 1.0 (0.8–1.3) 0.171
GFR at unplanned
termination of treatment
in mL/min, median (IQR)
21.0 (9–28) 65 (NA)c 0.020
Creatinine at discontinuation/
end of treatment,
median (IQR)
2.8 (2.2–5.7) 1.0 (NA)c 0.242
Ototoxicity 2 (7%) 0 0.185
Vestibular toxicity 1 (3%) 0 0.435
Skin rash 0 2 (5%) 0.501
Haematological abnormalities 0 1 (3%) 1.000
Change from A+G to A+Cd 13 (43%) 1 (3%) <0.001
Surgical treatment 15 (50%) 15 (39%) 0.338
Mortality (%)
In-hospital mortality 8 (27) 9 (23) 0.732
1-year mortality 9 (30) 10 (26) 0.688
Relapses 2 (3) 3 (8) 1.000
aThe seven patients in the A+G arm had high-level resistance to streptomycin
only; among the HLARa patients treated with A+C, five presented high-level
resistance to streptomycin only, six to gentamicin only, and seven to both
aminoglycosides.
bPatients on haemodialysis were excluded from the assessment of renal function
and toxicity.
cNA, not applicable. Only one patient treated with A+C had to discontinue
treatment.
dTwo patients with HLAR (to streptomycin only) and 11 with non-HLAR strains
switched from A+G to A+C during treatment (p 0.113). Median duration of the
aminoglycoside course did not differ between the groups (23.9 and 26.8 days,
respectively; p 0.984). One patient treated with A+C had to discontinue
treatment owing to severe skin rash.
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are shown in Table 1. IE cases produced by HLGR strains were
more frequently diagnosed in the latter period of the study
(p 0.018) and in healthcare-associated cases (p 0.008), while
no other relevant differences between groups were found.
Effect of antimicrobial treatment on outcome
No differences in baseline characteristics were detected in the
general clinical characteristics and outcome of the cohort
according to the type of treatment. However, an overwhelm-
ing increase in the use of A+C was detected over time
(Fig. 1b), in parallel with the HLAR rate. No differences were
detected between patients receiving A+G and those receiving
A+C with respect to clinical presentation, severity of IE or
surgery rates. The Kaplan–Meier survival analysis in Fig. 2b
shows that 1-year mortality was not significantly different
between those patients initially treated with A+G and those
treated with A+C (29% vs. 26%, respectively). In-hospital
mortality was 27% in the A+G group and 23% in the A+C
group (p 0.732). The relapse rate was very low, with no
statistically significant differences between the groups (three
relapses in the A+C group and two in the A+G group;
p 1.000). Due to the multiple changes introduced in the
manuscript along the several revisions performed, we consider
that Supplementary Material referring to relapses management
is not necessary.
Patients receiving A+G presented a higher incidence of renal
failure during treatment (65% vs. 34%; p 0.014), although no
differences were found in other types of treatment-induced
toxicity. In the A+C group, only one patient had to discontinue
treatment owing to a severe skin rash. Two patients in the A+C
group presented C. difficile-associated diarrhoea that did not
require discontinuation of treatment. In both cases, treatment
with oral vancomycin was sufficient to achieve a cure.
More A+G patients than A+C patients had to discontinue
treatment owing to toxicity (43% and 3%, respectively;
p 0.001) (Fig. 2a). Thirteen patients switched from A+G to
A+C a median of 18 days after initiation of A+G (range, 5–
30 days; IQR, 15–24.5 days). The reason for switching was
impaired renal function in 10 cases and persistent bacteraemia
in the remaining three patients. Among these 10 patients
initially treated with A+G who had to discontinue treatment
owing to renal failure and switched to A+C, GFR improved by
a median of 15.0 mL/h (IQR, 7.5–34.5), and serum creatinine
decreased by 1.3 mg/dL (0.8–3.8). At the end of treatment,
GFR and serum creatinine were 37.0 mL/h (22.0–53.8) and
1.8 mg/dL (1.1–1.98), respectively. Four of these patients died,
three during admission (at days 5, 23 and 44 after switching
treatment).
Aminoglycosides were administered QD in 3% of patients,
BID in 23% and TID in 74%. Treatment duration was not
statistically different between patients initially treated with
A+G and those treated with A+C (median of 42 days in both
groups). Length of treatment with A+C did not reach 8 weeks
in any of our patients. We did not find worse outcomes
(relapses and mortality) in patients treated with A+C for
6 weeks than in those treated with 4 weeks of A+G.
Prognostic factors of EFIE
Table 3 shows the predictive variables associated with 1-year
mortality. The only variables selected for logistic regression
analysis were year of diagnosis, presence of diabetes and
chronic renal failure, median Charlson score, occurrence of
heart failure during treatment, and surgical treatment of EFIE.
As mean Charlson score was collinear with diabetes and
chronic renal failure, this variable was not included in the
model. Table 4 shows the results of the logistic regression
analysis to find independent risk factors for 1-year mortality.
Only heart failure (OR, 4.3; 95% CI, 1.2–15.4; p 0.024) and
chronic renal failure (OR, 4.3; 95% CI, 1.2–14.7; p 0.021) were
independently associated with mortality. Neither the type of
antimicrobial regimen (OR, 0.7; 95% CI, 0.2–2.2; p 0.549 after
forcing its inclusion in the model) nor the period of diagnosis
affected mortality.
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FIG. 1. Evolution of HLAR and treatment of EFIE over time. (a)
Evolution of HLAR over time. (b) Evolution of EFIE antibiotic
treatment over time.
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Discussion
The general features of our cohort did not differ from those of
other EFIE cohorts described in global series and guidelines
[1,7,12,15]; namely, 13% prevalence of IE episodes, older
patients with comorbidities, need for surgery in fewer than half
of the patients (44%), 7% frequency of relapses, and around
30% mortality. The high percentages of healthcare-acquired
EFIE (75%) [1,5] and PVIE (33%) [8] are consistent with the
findings of other previous studies.
Interestingly, we found an increase in HLAR rates in recent
years, mainly because of the increased prevalence of HLGR.
Rates from the first two periods (1997–2006) are consistent
with those described by the European Centre for Disease
Prevention and Control for the period 2001–2007 [22], but
are clearly higher in the third period (2007–2011). While
evidence from randomized trials evaluating antimicrobial
therapy for EFIE is lacking, rates of resistance to classic
treatment options continue to increase [23,24]. The largest
multicentre cohort studies considering the characteristics and
evolution of EFIE do not generally include the effect of HLAR
on outcome [3], although this has traditionally been consid-
ered one of the major determinants of EFIE management,
relapses and mortality [25,26]. In this regard, no study has
assessed the development of HLAR in EFIE over time, although
there is some evidence of a clear increase in the prevalence of
HLAR strains [4,27–30]. While almost no relapses were
described in EFIE treated with A+G in the 1980s [17], most
recent series reported relapse rates of 7–10% [4,14]. How-
ever, we found no statistically significant differences in the
requirement for surgery, relapses or mortality according to
HLGR. We hypothesize that this may be because of the
efficacy of A+C against HLGR strains.
The in vitro efficacy of double beta-lactam therapy was first
described in the mid-1990s [31] and has since been proved in
(a)
(b)
FIG. 2. Kaplan–Meier survival analysis
curves. (a) Treatment discontinuation at
60 days. (b) 1-year mortality.
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animal models [32,33] and in a small non-randomized clinical
trial performed in Spain [14]. On the basis of this evidence, the
combination A+C was included in the 2005 American and
2009 European guidelines as an option for HLAR or multire-
sistant strains [12,15]. As stated above, A+C almost com-
pletely replaced A+G in our cohort during the study period.
This change did not lead to lowermortality over time, although a
significantly lower treatment discontinuation rate was detected
with A+C (p 0.001). A+C has been shown to be a safer option in
terms of renal impairment during treatment. This is a valuable
feature for a combination whose target population is at high risk
of nephrotoxicity. Some of ourmain findings coincidewith those
of Fernandez-Hidalgo et al. [34], who recently found similar
outcomes with A+C and A+G for EFIE.
The guidelines of the AHA (2005) [12] and of the ESC
(2009) [15] recommend 4 weeks of A+G for patients with
uncomplicated NVIE and 6 weeks for patients with PVIE and
patients with a > 3-month history of symptoms before
diagnosis. In the case of A+C, which is considered an option
for HLAR strains, 8 weeks is always recommended in both
guidelines. Length of treatment with A+C did not reach
8 weeks in any of our patients. However, 6 weeks of
treatment with A+C did not lead to poorer outcomes than
those obtained with the standard A+G regimen for non-HLAR
EFIE. Because the number of patients treated with 4 weeks of
A+C is small, we cannot recommend the 4-week A+C regimen
until further data on its efficacy are available. Nevertheless,
based on the results of our group and those of Fernan-
dez-Hidalgo et al. [34], a recommended duration of 6 weeks of
A+C seems sufficient.
Dahl et al. [35] recently demonstrated equivalent efficacy
and reduced nephrotoxicity of ampicillin plus short-course
gentamicin (2 weeks) and the standard regimen in a cohort of
84 patients with non-HLAR EFIE. They also demonstrated the
same efficacy for both the QD regimen and the TID regimen,
which is the recommended option in the AHA guidelines [12].
Median duration of aminoglycosides in our cohort was 28 days
(IQR, 15–32 days), and most patients received treatment TID.
The sample size is too small to detect relevant differences
between regimens. In our cohort, renal toxicity was recorded
and aminoglycosides withdrawn after a median of 18 days; this
supports the conclusion of Dahl et al. that 2 weeks of
aminoglycosides might be preferable to 4–6 weeks. As we
recently stated elsewhere, currently available evidence leads us
to conclude that, in cases of HLAR, A+C should be the first
choice [36]. Furthermore, the results of both the Fernandez--
Hidalgo study [34] and our study support the finding that A+C
has similar efficacy to A+G and is safer in EFIE patients without
HLAR treated with A+G for 4–6 weeks. The question of
which approach (ampicillin plus short-term gentamicin
(2 weeks) or A+C) is best for these patients remains
unanswered. A randomized controlled study is needed to
provide more conclusive data [36].
Our study has several limitations. First, it is not randomized.
Second, statistical power is limited owing to the small sample
size. Third, in contrast to other studies, referral bias probably
TABLE 3. Univariate analysis of risk factors associated with
1-year mortality in endocarditis due to Enterococcus faecalis
One-year
mortality
(N = 19)
Alive
(N = 50) p
Mean age (SD) in years 70.1 (11.2) 69.6 (12.1) 0.979
Male gender (%) 12 (63) 32 (64) 0.948
Year of diagnosis (%)
1997–2006 13 (68) 21 (42) 0.050
2007–2011 6 (32) 29 (58)
HLGR 3 (16) 10 (20) 1.000
Predisposing conditions and underlying diseases (%)
Diabetes mellitus 9 (47) 14 (28) 0.127
Chronic renal failure 8 (42) 9 (18) 0.059
Haemodialysis 2 (11) 3 (6) 0.611
History of cancer 6 (32) 10 (20) 0.347
HIV infection 1 (5) 0 0.275
Chronic liver disease 3 (16) 5 (10) 0.675
Chronic lung disease 2 (11) 13 (26) 0.206
Transplantation 0 1 (2) 1.000
History of infective endocarditis 1 (5) 8 (16) 0.427
Mean Charlson score (SD) 3.0 (2.0) 2.2 (1.5) 0.035
Healthcare acquisition (%) 16 (84) 36 (72) 0.363
Type of endocarditis (%)
Native valve 13 (68) 32 (64) 0.446
Prosthetic valve 5 (26) 17 (34)
Pacemaker lead 1 (5) 1 (2)
Valve involvement (%)
Aortica 12 (63) 32 (64) 0.312
Mitral 5 (26) 17 (34)
Right-sideb 2 (11) 1 (2)
Complications (%)
Heart failure 13 (68) 20 (40) 0.035
Renal failure 10 (53) 20 (40) 0.344
Systemic emboli 7 (37) 14 (28) 0.476
Perivalvular abscess 3 (16) 3 (6) 0.429
Persistent bacteraemia 3 (16) 3 (6) 0.334
Surgical treatment (%) 6 (32) 24 (48) 0.219
Treatment groups (%)
A+G 9 (47) 21 (42) 0.788
A+C 10 (53) 29 (58)
aPatients with aortic IE had concurrent infection of their intracardiac device (two
patients), mitral native valve (nine cases), mitral plus tricuspid native valve (one
case) and tricuspid native valve (one case).
bRight-sided IE consisted of intracardiac device infection (two cases) and
pulmonary native valve infection (one case). A+G, ampicillin plus gentamicin;
A+C, ampicillin plus ceftriaxone.
TABLE 4. Multivariate analysis of risk factors associated with
1-year mortality in endocarditis due to Enterococcus faecalis
Univariate analysis Multivariate analysis
OR 95% CI p OR 95% CI p
Year of diagnosis
2007–2011 vs. 1997–2006
0.2 0.4–1.0 0.05 – – –
Diabetes mellitus 2.5 0.7–9.3. 0.155 – – –
Chronic renal failure 2.6 0.6–10.4 0.191 4.3 1.2–15.4 0.024
Heart failure 7.5 1.8–31.6 0.006 4.3 1.2–14.7 0.021
Surgical treatment 0.5 0.1–1.6 0.226 – – –
Treatment groupsa
A+C vs. A+G 1.5 0.3 6.4 0.7 0.2–2.2 0.549
aThe variable A+C vs. A+G was forced into the final regression model for
theoretical reasons.
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led us to include non-standard EFIE patients, namely, younger
subjects with a high likelihood of surgical management, higher
prevalence of healthcare-associated infection (75%), and
antibiotic treatment at the time of referral. Fourth, we
considered that renal failure in patients receiving aminoglyco-
sides was at least partially attributable to aminoglycoside
toxicity, which involves a risk of overestimation. Fifth,
aminoglycoside trough levels and data on concomitant use of
nephrotoxic agents are not provided. And finally, a possible
historical bias leading to better results in the A+C group due
to significantly later and improved general medical care could
have affected some results.
In conclusion, the efficacy of A+C administered for 6 weeks
appears similar to and safer than that of A+Gadministered for 4–
6 weeks according to AHA and ESC recommendations for the
treatment of EFIE. A+C is the preferred regimen for HLAR
strains. This combination presents lower rates of discontinua-
tion due to toxicity than a 4–6-week course of A+G in patients
with non-HLAR EFIE. Although HLAR rates have increased over
time, HLGR EFIE did not have a worse prognosis than
non-HLGR EFIE. As a consequence, the treatment of EFIE in
Spain has shifted from A+G to A+C in recent years.
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